About the clinic

A new chapter in interventional psychiatry — rooted in real medicine.

Trellis Pathway is a physician-led ketamine and Spravato® clinic opening in East Islip, New York in Fall 2026. It is the sister practice to PsychVisit, a mental health clinic founded and led by Faisal Rafiq, MD, built to bring careful, evidence-based ketamine therapy to patients on the South Shore of Long Island.

Opening
Fall 2026
Location
East Islip, NY
Medical Director
Faisal Rafiq, MD
Sister practice
PsychVisit
Faisal Rafiq, MD — founder and medical director of Trellis Pathway
Founder · Medical DirectorFaisal Rafiq, MD
The Physician

Faisal Rafiq, MD

Dr. Rafiq is a board-certified psychiatrist and the owner of both PsychVisit and Trellis Pathway. At PsychVisit he has spent years caring for patients living with depression, anxiety, PTSD, and treatment-resistant mood disorders — the same patients who, again and again, asked for something more than another medication trial.

Trellis Pathway is his answer: a dedicated interventional psychiatry clinic built around one careful pathway — in-person evaluation, supervised induction, and continued care at home with real physician oversight. No app. No shortcuts. Just medicine done well.

The Sister Practice

PsychVisit

PsychVisit is Dr. Rafiq's established mental health practice, providing psychiatric evaluations, medication management, and ongoing care for patients across the region. It is the clinical home where many Trellis Pathway patients will first be seen and continue their long-term care.

Trellis Pathway extends that same standard of care into ketamine and Spravato® therapy — held to the same diagnostic rigor, the same follow-up cadence, and the same physician accountability that PsychVisit patients have come to expect.

Join the waitlist

We're seeing our first patients in Fall 2026.

Spots will be limited. Add your name to the waitlist and our care team will reach out as the clinic opens — no commitment, just a conversation.

Physician-led ketamine and Spravato therapy held together by one careful pathway.

Medical disclaimer. Ketamine and Spravato® are prescription medicines. At-home and IV ketamine are administered off-label for mood and pain conditions; Spravato® (esketamine) is FDA-approved for treatment-resistant depression and administered under a REMS program. All treatment requires an in-person physician evaluation and ongoing clinical oversight. This page is educational and does not constitute medical advice. Results vary; treatment may not be appropriate for every patient. If you are in crisis, call or text 988.